The German partner of DNAPrint Genomics Inc. has the go-ahead to begin its first human study of a drug intended to prevent migraine headaches. Biofrontera AG, in which DNAPrint owns a nearly 10 ...

DNAPrint genomics Inc. said it would acquire some of the assets of Ellipsis Biotherapeutics Corp. in a stock deal valued at about $112,000. Ellipsis will sell its clinical genomics and genotyping ...

DNAPrint Genomics Inc. Annual stock financials by MarketWatch. View the latest DNAG financial statements, income statements and financial ratios.

SARASOTA -- DNAPrint Genomics posted a loss of $906,292 during the first quarter as it continued efforts to milk profits out of its genetic testing products. The per-share measure of the loss is so ...

SARASOTA, Fla., June 22, 2006 (PRIMEZONE) -- DNAPrint Genomics, Inc. (OTCBB:DNAG) President and Chief Executive Officer Richard Gabriel told shareholders at the Annual Meeting today that the ...

DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that representatives of Ellipsis Biotherapeutics Corporation, a wholly owned subsidiary of DNAPrint Genomics, will exhibit at the American Society ...

SARASOTA -- DNAPrint Genomics Inc. continued its financial losing streak in 2002, finishing the year $3.11 million in the red. That's compared with a $2.59 million loss in 2001. Since December 1998, ...

DNAPrint Genomics Inc. Annual cash flow by MarketWatch. View DNAG net cash flow, operating cash flow, operating expenses and cash dividends.

In our ongoing attempt to adhere to the public schedule, I would like to introduce the next company in this afternoon’s program. DNAPrint is a biotechnology company dedicated to the development of ...

DNAPrint Genomics, Inc. engages in the research and development of genomics-based products and services for biomedical and forensics. The company was founded by Tony N. Frudakis on January 3, 1983 and ...